Kazakhstan is set to manufacture radiopharmaceuticals for the treatment of prostate cancer and neuroendocrine diseases, Report informs via local media.
During the 68th session of the International Atomic Energy Agency (IAEA) General Conference, Kazakh specialists presented their achievements in the field of nuclear medicine at the event, with IAEA experts acknowledging the high level of implementation of bilateral cooperation programs. Over the next three years, the country plans to open seven centers equipped with positron emission tomography (PET) scanners, four centers with single-photon emission computed tomography (SPECT) scanners, and five new nuclear medicine centers through public-private partnerships.
Yelena Chakrova, head of the Center for Radiochemistry and Isotope Production, stated that Kazakhstan currently produces seven radiopharmaceuticals with technical cooperation from the IAEA. Zhandos Amankulov, a representative of the Kazakh Research Institute of Oncology and Radiology, highlighted the effectiveness of public-private partnerships in making nuclear medicine methods more accessible to the majority of the country's citizens.